Skip to contentpdufa.bio

AG-236 Phase

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

AG-236 Phase is an Agios Pharmaceuticals program in polycythemia vera. Its next catalyst is a Readout on Dec 13, 2026.

AGIO catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Indication under review: polycythemia vera. Sponsor: Agios Pharmaceuticals (AGIO). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Dec 13, 2026AGIO

Questions

When is AG-236 Phase's next FDA decision or readout?

The next tracked catalyst for AG-236 Phase is a Readout on Dec 13, 2026.

What happened at AG-236 Phase's most recent FDA decision?

No FDA decision for AG-236 Phase is in our archive yet.

What is AG-236 Phase used for?

In our records AG-236 Phase is under review or in development for polycythemia vera.

Who makes AG-236 Phase?

Agios Pharmaceuticals (AGIO).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.